This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Eng-King Tan, MD, FRCP

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with interest the article by Kleiner-Fisman and Fisman¹ where they highlighted a 16% prevalence of peripheral edema presumably induced by pramipexole in patients with Parkinson disease (PD). This was consistent with the finding in the CALM-PD study² but much higher than the 5% in some of the earlier studies.³ Although the authors suggest that the 16% prevalence may be an overdiagnosis due to the retrospective nature of the study, there are a number of considerations that need to be examined before comparisons with published figures can be reliably made. These include problems in the recognition and diagnosis of peripheral edema and the interpretation of the causal relationship between pramipexole and this potential adverse medical complication.

In most situations, it's the patients who draw their physicians' attention to the swollen limbs. Whether it is in clinical trials or in routine neurological consultations, unless the physician . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

Peripheral Edema and Dopamine Agonists in Parkinson Disease—Reply
Galit Kleiner-Fisman and David N. Fisman
Arch Neurol. 2007;64(10):1547.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Galit Kleiner-Fisman and David N. Fisman
Arch Neurol. 2007;64(6):820-824.
ABSTRACT | FULL TEXT